Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Oye Therapeutics Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and are located in 2 distinct art units. This distribution suggests that the company's technology is being evaluated by two different administrative groups within the patent office. Working with 2 distinct art units requires a flexible prosecution strategy to meet the potentially different technical standards of each unit. The company's current patent activity is thus decentralized across multiple points of contact.
Luisalberto Gonzalez is the busiest examiner for this portfolio, currently handling 1 pending office action. With 2 distinct examiners each responsible for one of the 2 pending office actions, the company's workload is evenly distributed. This arrangement ensures that no single examiner has total control over the company's current active applications. The presence of 2 distinct examiners across 2 distinct art units indicates a diversified approach to their current filings in the Biotechnology & Pharmaceuticals sector, allowing for independent review paths for their innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034142 | Caffeine Compositions | GONZALEZ, LUISALBERTO | — |
| 17784375 | Caffeine Citrate Formulations | CHICKS, ASHLI ARIANA | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034142 | Caffeine Compositions | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 17784375 | Caffeine Citrate Formulations | CHICKS, ASHLI ARIANA | 1626 | §112DP | Final Rejection | — | Pending | Jun 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOye Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Luisalberto Gonzalez has the most, with 1 of Oye Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
